Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
4h agoEli Lilly boosts full-year forecast as weight-loss drug demand surges
Eli Lilly and Company raised its 2025 revenue and adjusted-EPS guidance after third-quarter sales of its weight-loss drug Zepbound reached US$3.6 billion and diabetes drug Mounjaro US$6.5 billion, both above analyst estimates. The company now expects adjusted EPS of US$23.00–23.70 and revenues of US$63–63.5 billion. Despite pressure from U.S. drug-price reform risks, strong growth in its incretin portfolio drove the upgrade and shares jumped more than 5% in pre-market trading.
Explore:Mutual Fund Home
positive
4h agoEli Lilly boosts full-year forecast as weight-loss drug demand surges
Eli Lilly and Company raised its 2025 revenue and adjusted-EPS guidance after third-quarter sales of its weight-loss drug Zepbound reached US$3.6 billion and diabetes drug Mounjaro US$6.5 billion, both above analyst estimates. The company now expects adjusted EPS of US$23.00–23.70 and revenues of US$63–63.5 billion. Despite pressure from U.S. drug-price reform risks, strong growth in its incretin portfolio drove the upgrade and shares jumped more than 5% in pre-market trading.
Explore:Mutual Fund Home
Breaking
positive
Eli Lilly boosts full-year forecast as weight-loss drug demand surges
about 4 hours ago
1 min read
70 words
Eli Lilly raises full-year forecast after blockbuster weight-loss and diabetes drug sales.
Eli Lilly and Company raised its 2025 revenue and adjusted-EPS guidance after third-quarter sales of its weight-loss drug Zepbound reached US$3.6 billion and diabetes drug Mounjaro US$6.5 billion, both above analyst estimates. The company now expects adjusted EPS of US$23.00–23.70 and revenues of US$63–63.5 billion. Despite pressure from U.S. drug-price reform risks, strong growth in its incretin portfolio drove the upgrade and shares jumped more than 5% in pre-market trading.
Eli Lilly and Company raised its 2025 revenue and adjusted-EPS guidance after third-quarter sales of its weight-loss drug Zepbound reached US$3.6 billion and diabetes drug Mounjaro US$6.5 billion, both above analyst estimates. The company now expects adjusted EPS of US$23.00–23.70 and revenues of US$63–63.5 billion. Despite pressure from U.S. drug-price reform risks, strong growth in its incretin portfolio drove the upgrade and shares jumped more than 5% in pre-market trading.
Companies:
Eli Lilly and Company
Tags:
stocks
pharma
stocks
pharma
healthcare
company earnings
growth
Oct 30, 2025 • 14:43 IST